1.71
-1.16%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About OPKO Health
From its filings with the US Securities and Exchange Commission
OPKO Health is based in Miami, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker OPK. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $606.9m and a net loss of $225.7m. At that date it held total assets of $1.93bn and shareholders' equity of $1.27bn.
We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA® (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for further development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of children and adolescents as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, have been secured in more than 50 markets worldwide, including in the United States, European Union Member States, Japan, Canada, and Australia under the brand name NGENLA®.
Through our pharmaceutical business, we manufacture and sell Rayaldee, a U.S. Food and Drug Administration (“FDA”) approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency. Rayaldee has secured marketing authorizations in 11 European countries, and we are advancing its development in mainland China through our strategic partners.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Nov 1995
- Employees
- 2,275
- Website
- opko.com ↗
- Head office
- 4400 BISCAYNE BLVD., MIAMI, FL, 33137
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Phillip FrostChairman of the Board, Chief Executive Officer, since 2007$2.2m
- Dr. Elias ZerhouniPresident, Vice Chairman of the Board, since 2022$2.1m
- Dr. Jane HsiaoVice Chairman of the Board, Chief Technical Officer, since 2007$2.1m
- Mr. Adam LogalChief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer$1.8m
- Dr. Charles BishopChief Executive Officer of OPKO Renal
- Dr. Tony CruzChief Executive Officer, Transition Therapeutics, Inc
- Mr. Steven RubinExecutive Vice President - Administration, Director, since 2007$1.8m
- Dr. Gary NabelChief Innovation Officer, Director, since 2022
- Dr. Richard KrasnoIndependent Director$84,900
- Mr. Prem LachmanIndependent Director$84,900
- Dr. Roger MedelIndependent Director$62,400
- Mr. John PaganelliIndependent Director, since 2003$77,400
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 4
- Social
- 55
- Governance
- 27
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Diverse Product Portfolio: OPKO Health Inc offers a wide range of products in the pharmaceutical and diagnostics industry, providing a diversified revenue stream.
- Strong Research and Development: OPKO Health consistently invests in research and development activities, allowing them to innovate and introduce new products or technologies to the market.
Weaknesses
- Regulatory Challenges: The company operates in a highly regulated industry and faces challenges in complying with various government regulations and obtaining necessary approvals.
- Financial Dependence: OPKO Health heavily relies on external funding and partnerships for its operations, which can impact its financial stability and flexibility.
Opportunities
- Growing Demand for Genetic Testing: With increased awareness and interest in personalized medicine, there is a growing market opportunity for OPKO Health's genetic testing products.
- Emerging Markets Expansion: Expanding into emerging markets with large populations and underdeveloped healthcare systems presents significant growth opportunities for the company.
Threats
- Intense Competition: The healthcare and diagnostics industry is highly competitive, with numerous established players and new entrants, which may negatively impact OPKO Health's market share and profitability.
- Regulatory and Legal Risks: Changes in regulations, lawsuits, or legal disputes can pose significant risks to the operations and reputation of OPKO Health.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.